Covid-19 Updates | Gene Therapy Market is projected to grow at an annualized rate of 45%, till 2030

Gene Therapy Market is projected to grow at an annualized rate of 45%, till 2030
Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio).
Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.
The USD 11.6 billion (by 2030) financial opportunity within the Gene Therapy Market has been analyzed across the following segments:
Read Detailed Report: https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

Leave a Reply

Your email address will not be published. Required fields are marked *